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SUMMARY
Objectives: To compare costs and clinical benefits of three additional therapies to met-
formin (MF) for patients with diabetes mellitus type 2 (DM2). Methods: A discrete event 
simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted 
life years [QALY]) of saxagliptine as an additional therapy to MF when compared to 
rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the 
economic impact of saxagliptine use in the context of the Brazilian private health sys-
tem. Results: The acquiring medication costs for the hypothetical patient group analyzed 
in a time frame of three years were R$  10,850,185, R$  14,836,265 and R$ 14,679,099 
for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower 
costs and greater effectiveness in both comparisons, with projected savings for the first 
three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings 
of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of 
a health plan with 1,000,000 covered individuals. Conclusion: From the perspective of 
private paying source, the projection is that adding saxagliptine with MF save costs when 
compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that 
have not reached the HbA1c goal with metformin monotherapy. The BIM of including 
saxagliptine in the reimbursement lists of health plans indicated significant savings on 
the three-year horizon.
Keywords: Health economics; diabetes mellitus type 2; health management; therapeu-
tics; pharmacy and therapeutics committee; cost-effectiveness assessment.
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INTRODUCTION
The prevalence of type 2 diabetes mellitus (DM2) contin-
ues to grow around the world and it is considered today a 
global epidemic. A study of global burden of diabetes mel-
litus has identified that, in 1995, there were 135 million 
people with diabetes in the world and there are projections 
that, in 2025, this figure will reach 300 million1. It is esti-
mated that 2/3 of these patients live in developing coun-
tries, and countries such as Brazil, India, and China will 
have twice as many patients with diabetes than the USA2,3.
Brazilian regional studies observed that DM2 preva-
lence varies between 7% and 13%4-7. However, the only 
Brazilian study of prevalence at national level was con-
ducted in the late 1980’s, showing a prevalence of diabetes 
in the population of 30-69 years of 7.6%8. After two de-
cades other studies were conducted, showing DM2 preva-
lences of 12.1% in the city of Ribeirão Preto/SP7, 12.4% in 
Porto Alegre/RS9, and 7.1% in Pelotas/RS7. The most re-
cent prevalence studies did not include the North, North-
east and Midwest regions of Brazil, which may mean that 
the estimates currently available do not comprehensively 
portray the DM2 national reality. Several factors are as-
sociated with the observed increase in the prevalence of 
diabetes mellitus in Brazil and worldwide. The most fre-
quently discussed were increasing life expectancy of the 
population, changes in lifestyle (including high-fat foods 
and sedentary lifestyle), and obesity1,10,11.
As a chronic condition with serious complications 
and high demand of care, DM2 is an expensive disease. 
Although published data have shown that improved gly-
cemic control can lead to better health outcomes, fewer 
than 50% of the Brazilian patients assessed in local stud-
ies reached the desired value for HbA1c12-14. Thus, strate-
gies directed to a better glycemic control of these patients, 
including new drugs used in combination with existing 
hypoglycemic agents, may improve the health status of pa-
tients with DM, reducing the complications15,16 and costs 
associated17-19. Saxagliptine (SAX) is a selective inhibitor of 
dipeptidyl peptidase-4 (DPP-4), whose safety and efficacy 
have been established in randomized studies that have ob-
served significant reductions in HbA1c in monotherapy or 
in additional therapy to metformin (MF)20-23. In the Brazil-
ian health system, public and private services coexist and 
account for about USD 70 billion per year, which corre-
sponds to nearly 7.5% of the country’s GDP. Currently, 37 
million (≈ 20%) Brazilian people have access to the pri-
vate health system. The economic analysis on health is a 
well-established method to assess the effectiveness of new 
drugs, and it is increasingly used as a managerial tool24,25. 
Whereas the data of cost-effectiveness in schemes with 
SAX for patients who have failed to achieve the goals of 
HbA1c with MF in Brazil are not available, the objective of 
this study is to compare the costs and benefits of additional 
therapies to metformin.
METHODS
DECISION-MAKING MODEL
A discrete event simulation model was designed to esti-
mate the incremental cost-effectiveness ratio of SAX as 
an additional therapy to MF versus the addition of rosi-
glitazone (ROS) or pioglitazone (PIO) in a hypothetical 
cohort of patients treated with MF without glycemic con-
trol. Such models are based on secondary data (obtained 
through systematic review of the literature) to estimate 
the outcome of a group of patients with the disease under 
analysis with each of the comparators, using computation-
al simulation resources.
The model was developed using data derived from the 
United Kingdom prospective diabetes study (UKPDS), 
which demonstrated the association between HbA1c, lev-
els of systolic blood pressure, and micro and microvascu-
lar complications15. The UKPDS outcomes model (a deci-
sion model built from the results of UKPDS) simulates the 
health results throughout the lives of patients with DM2 to 
predict the occurrence and moment of seven DM-related 
complications (myocardial infarction [MI], congestive 
heart failure [CHF], stroke, amputation, terminal stage re-
nal disease [TSRD], and blindness) and calculate the life 
expectancy and the quality-adjusted life years (QALYs)26.
The main characteristic of the model type used is the 
ability to generate a hypothetical cohort of patients, with 
DM2 (n = 1,000) for each therapeutic approach and as-
sign different demographic profiles and a set of risk factors 
(body mass index [BMI], total cholesterol, HDL choles-
terol, systolic blood pressure, and HbA1c) for each one, 
allowing the simulation of the behavior of patients treated 
according to their baseline risk of events. Regarding en-
try in the model, all patients are in monotherapy with MF 
with uncontrolled blood glucose. At this stage they start 
one of the three strategies and their progression and the ef-
fect of the treatment are then simulated at one-year inter-
vals, after which the results of health and cost of the treat-
ment are updated. The occurrence of fatal and non-fatal 
events depends on the demographic profile of the patient, 
attributed clinical characteristics, and risk equations based 
on the data in UKPDS. The simulation is run for 1,000 pa-
tients and ten repetitions where the mean results are pro-
vided for costs and benefits. During the evolution, when 
patients are above the HbA1c threshold (≥ 7.5%), they re-
ceive rescue therapy with NPH insulin and MF. To test the 
model stability related to the variability and uncertainty 
in the parameters and assumptions followed, two differ-
ent strategies were used (univariate sensitivity analysis and 
probabilistic sensitivity analysis), with a variation of the 
following parameters: utility values, probability of adverse 
events, characteristics on baseline and costs. Additional 
data are available from the authors and can be supplied to 
interested parties. 
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PATIENT PROFILES AND TREATMENT EFFECT
The characteristics on baseline followed in the model 
are shown in Table 1 and were obtained from analyses 
of the subgroup of patients on monotherapy with MF in 
DIAPS7927, a Brazilian study of clinical outcomes and cost 
of DM2 on the private health system. The model uses dif-
ferent profiles of efficacy and safety for each comparator 
expressed by the treatment effect on HbA1c, cardiovas-
cular risk factors and adverse events (Table 1)28-31. For the 
case-base, the decrease in HbA1c in the first year was based 
on a published meta-analysis32, the duration of the benefit 
was established as 12 months, no delay at the beginning 
of HbA1c modification was assumed, and the slope of the 
curve was set as 0.759 (defined by a nonlinear function). 
Both comparators showed similar results in terms of re-
duction of HbA1c. Consequently, the progression curves 
overlap over time.
COST DATA AND UTILITIES WEIGHTS
The annual cost data inserted in the model are related to 
the purchase of medicinal products, control of adverse 
events and treatment of complications for DM2. All costs 
were discounted at an annual rate of 5%. Medication costs 
were obtained from official lists and the mean doses of the 
DIAPS79 study. The source of cost data related to micro 
and macrovascular complications was also the DIAPS79 
study, except for the costs related to the maintenance of pa-
tients with TSRD (Table 2), which were not available from 
that study and were based on assumptions from the repay-
ment of the public health system (as an approximation of 
values in the private health, due to the lack of specific data).
The utility values are weights attributed to health states 
and reflect the patients’ preferences for each state on a 
scale of 0 (death) to 1 (best imaginable health state). When 
an event (complication or death) occurs in the model, the 
patient receives a factor that is subtracted from the mean 
utility allocated to patients without complication. The util-
ity reduction coefficients were obtained from UKPDS62, 
with the exception of TSRD and blindness33,34. QALYs 
were calculated by multiplying the time spent in the status 
of health by the utility of the health status (Table 2)35.
BUDGET IMPACT MODEL (BIM)
A BIM was designed to simulate the economic impact of 
using SAX in patients with DM2 and uncontrolled blood 
glucose in a time frame of three years. The BIM analysis 
combines epidemiological data, estimates of market share 
and treatment costs to predict the eligible population and 
the total investment needed to deliver a new drug to pa-
tients. The BIM was designed considering a health plan 
with 1,000,000 individuals and only the costs relating to 
the purchase of medicines were considered, since other 
medical costs are not significantly different among the 
comparators in short-term time frames. The expected an-
nual cases of DM2 were calculated by applying the Brazil-
ian data of prevalence adjusted by age7,36 and the annual in-
crement of cases is a result of the ageing of the population 
and the increased prevalence of the disease among older 
individuals. Table 2 presents input data for the BIM. To es-
timate the current market share that would be replaced by 
SAX, data from a national survey that assesses the sales of 
medicines in pharmacies in Brazil were combined with the 
mean dose reported in DIAPS79. The assumption followed 
was that the market share for SAX would rise from 0.35% 
in the first year to 1.95% in the third year, mainly due to 
the replacement of TZDs and, to a lesser extent, due to the 
replacement of sulfonylurea.
RESULTS
Compared with the addition of ROS to the ongoing therapy 
with MF, SAX was estimated to avoid 12.3 vascular events 
(5.3 fatal cases). When compared to PIO, SAX resulted in 
an incremental benefit of 15.0 vascular events avoided (3.5 
fatal cases). The acquisition costs of the medication for the 
assessed cohort were R$ 10,850,185, R$ 14,836,265, and 
R$ 14,679,099 for SAX, PIO and ROS, respectively. Hos-
pitalization and treatment of adverse events were the main 
components of the cost, representing 67.2%, 59.9% and 
60.2% of the total costs for SAX, PIO and ROS, respec-
tively. Both comparisons point to the additional therapy of 
SAX as being cost-saving (more effective and less costly), 
with projected savings for the first three years of R$ 3,874 
and R$ 3,996, respectively (Table 3).
In the univariate sensitivity analysis, SAX remained 
dominant compared to TZDs after a variation of +/-15% 
on all selected parameters. HbA1c and costs were the pa-
rameters that impacted the model, since the baseline level 
of HbA1c directly affects the amount of time that patients 
will remain under treatment with SAX or TZDs. In proba-
bilistic analyses, adding SAX to the MF therapy was domi-
nant in 62.1% and 76.6% of all scenarios versus the addi-
tion of PIO or ROS, respectively. Only in 2.2% and 1.5% of 
the simulations did SAX show less effectiveness and higher 
costs, enhancing the consistency of the observed results. 
Additional information (including sensitivity analysis 
graphs and additional details for results of cost-effective-
ness) can be obtained by contacting the authors.
The BIM estimated cumulative savings of R$ 417,958 
with the reimbursement of SAX in 3 years. Considering 
the cost per patient eligible for treatment with SAX, the 
model estimated annual savings that rise gradually until 
year three, when it reaches 6.6%. Univariate sensitivity 
analysis was conducted to assess the impact of the main 
parameters in the final results (prevalence of DM, mar-
ket share and drug acquisition costs). A variation range 
of ± 25% was assumed for the sensitivity analysis but the 
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Basal characteristics
Parameter Value Source
Median age (years) 59.77 DIAPS79
% of women 0.58 DIAPS79
Mean duration of DM2 (years) 7.27 DIAPS79
Mean height (meters) 1.61 DIAPS79
% of Afro-caribbean 0.15 DIAPS79
% of smokers 0.10 DIAPS79
Mean HbA1c (%) 6.47 DIAPS79
Mean total cholesterol (mmol/L) 4.44 DIAPS79
Mean HDL cholesterol (mmol/L) 1.22 DIAPS79
Mean systolic BP (mmHg) 123.57 DIAPS79
Mean weight (kg) 78.76 DIAPS79
Clinical history of (%)
Atrial ﬁbrillation 1.1% DIAPS79
Peripheral vascular disease 3.3% DIAPS79
Ischemic heart disease 12.0% DIAPS79
Myocardial infarction 2.2% DIAPS79
Congestive heart failure 4.3% DIAPS79
Stroke 3.3% DIAPS79
Amputation 0.0% DIAPS79
Blindness 0.0% DIAPS79
TSRD 0.0% DIAPS79
Treatment effect parameters
Parameter
Treatment Control Rescue
MF+SAX* MF+PIO MF+ROS MF+INS§ 
HbA1c
Reduction in 1st year -0.69 -0.64§§ -0.63 -2.10
Months with beneﬁt (1st year) 12 12 12 12
Delay in HbA1c modiﬁcation 0 0 0 0
Slope (per year) 0.759 0.759 0.759 0.759
Risk factors
Systolic blood pressure 0 0 0 0
Total cholesterol (mmol/L) 0 0.138 0.27 0
HDL cholesterol (mmol/L) 0 0.159¥ 0.08¶ 0.07
Weight (kg) -0.28 1.54 1.54 3.500
Adverse events
Hypoglycemia
Symptomatic events 0.01 0 0.01 0.47
Nightly events 0 0 0 0
Serious events 0 0 0 0
DM2, diabetes mellitus type 2; BP, blood pressure; TSRD, terminal stage renal disease; MF, metformin; SAX, saxagliptine; PIO, pioglitazone; 
ROS, rosiglitazone ; INS, insulin; *DeFronzo22; §Yki-Järvinen28; §§Mwamburi31; ¥Polonsky29; ¶Stewart30.
Table 1 – Basal characteristics of patients and treatment effect parameters
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Table 2 – Costs, utilities weights and input parameters in budget impact model
Direct medical costs
Therapy Annual cost of acquisition Source
Metformin + saxagliptine 2.133 DIAPS79*
Metformin + pioglitazone 2.889 DIAPS79
Metformin + rosiglitazone 2.859 DIAPS79
Metformin + insulin 1.066 DIAPS79
Adverse event Event cost Source
Serious hypoglycemia 0 Assumption
Symptomatic hypoglycemia 0 Assumption
Nocturnal hypoglycemia 0 Assumption
Complication Event cost Maintenance Source
Ischemic heart disease 7.311 704 DIAPS79
Myocardial Infarction 8.651 704 DIAPS79
Congestive heart failure 4.843 704 DIAPS79
Stroke 7.634 704 DIAPS79
Amputation 2.182 872 DIAPS79
Blindness 0 872 DIAPS79
TSRD 4.438 22.464** DIAPS79
Health state utility weight Value Source
Baseline 0.885
United Kingdom 
Research
Utility reduction Value Source
Ischemic heart disease -0.090 UKPDS 62
Myocardial infarction -0.055 UKPDS 62
Congestive heart failure -0.108 UKPDS 62
Stroke -0.164 UKPDS 62
Pre-blindness -0.029 UKPDS 62
Blindness -0.074 Currie 2006 
TSRD -0.263 Currie 2006
Kidney transplant -0.075 UKPDS 62
Amputation -0.280 UKPDS 62
BMI -0.014 UKPDS 62
Parameters for budget impact model ingress 
Parameter Year 1 Year 2 Year 3 Source
Individuals covered 1,000,000 1,000,000 1,000,000 Assumption
Prevalence of DM 4.77% 4.88% 4.99% Calculated
% of diagnosed among the prevalent cases of DM 76.0% 90.0% 90.0%
Decision 
resources
% of DM2 among patients w/DM 90.0% 91.1% 91.1% Winer 2004
% of patients with DM2 w/OGLD 91.1% 53.3% 53.3% DIAPS79
% of uncontrolled DM2 (HbA1c > 10% of 
the reference value)
53.3% 76.0% 76.0% DIAPS79
BMI, body mass index; DM, diabetes mellitus; DM2, diabetes mellitus type 2; TSRD, terminal stage renal disease; *DIAPS79, data on ﬁle; 
**assumption based in 3 hemodialysis sessions per week with a unit cost of R$ 144 per session (source: Ofﬁcial List of Public Health System).
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conclusion of SAX as an economically viable option re-
mained practicable even by varying the parameter with 
the greatest impact on final results (acquisition cost of 
SAX; -R$ 131,130 in 3 years). 
DISCUSSION
DPP-4 inhibitors such as SAX are new therapies with 
proven efficacy as adjuncts to MF for patients who have 
failed to achieve the goal of HbA1c in monotherapy but 
new anti-hyperglycemic medications can have higher unit 
costs compared to previous well-established therapeutic 
options. More comprehensive assessments, considering 
total costs of treatment and expected health benefits, can 
help decision-makers analyze whether higher acquisition 
costs may be offset by higher therapeutic results, leading 
to future projected savings for the private health care sys-
tem. Decision-making supported in economic appraisal is 
a reality in several countries where political guidelines and 
reimbursement lists are developed using cost-effectiveness 
results. An example is the recommendation of additional 
therapy with DDP-4 inhibitors for patients with poor gly-
cemic control in the United Kingdom, supported by re-
sults also obtained from the UKPDS Outcomes Model37,38.
A systematic review on cost-effectiveness of interven-
tions in DM2 found strong evidence to classify the inten-
sive glycemic control, as proposed in UKPDS, compared 
to conventional glycemic control as a very cost-effective 
strategy39. In other contexts DDP-4 inhibitors proved to 
be a cost-effective additional therapy when compared to 
other oral anti-hypoglycemic medications40,41. The addi-
tion of SAX to MF therapy in patients who did not reach 
the HbA1c goal proved to be a resource-saving strategy in 
this study. Additionally, the budget impact analysis indi-
cated that the reimbursement of SAX would lead to signifi-
cant cost savings from the perspective of a private paying 
source in the first three years. The BIM did not consider 
costs occurring from adverse events to ensure a conserva-
tive approach, since the DPP-4 class has the most favorable 
safety profile among all oral hypoglycemic medications32, 
thus higher savings could be obtained as a result of lower 
costs related to adverse events. The Brazilian data regard-
ing cost-effectiveness of interventions to treat and prevent 
long-term complications of DM are still scarce. Neverthe-
less, studies of the disease cost have become increasingly 
frequent, especially those dealing with the economic bur-
den of the chronic complications of DM14,17,19.
The association between glycemic control and occur-
rence of DM complications is well-established and it is 
believed that strategies targeting the maintenance of ad-
equate levels of HbA1c reduce costs related to complica-
tions15,42,43. The simulation model used in this study was 
able to reproduce the long-term benefits of glycemic con-
trol by reducing the risk of MI, CHF, stroke, amputation, 
TSRD, and blindness. Generally, the difficulty to main-
tain patients with DM2 within glycemic control targets 
is acknowledged, as evidenced by Brazilian studies that 
assessed this issue12-14. It is known that the causes of this 
problem are multifactorial and include issues related to 
changes in lifestyle and compliance with the drug treat-
ment. Despite the complexity of the matter, it is believed 
that new therapeutic strategies targeting the subgroup of 
patients who did not achieve control with MF alone can 
improve this scenario, as estimated specifically for SAX in 
this study.
Table 3 – Incremental results of case-base (additional therapy of saxagliptine versus comparators)
Saxagliptine + Metformin 
versus 
Pioglitazone + Metformin
Comparator Costs (R$) QALY Cost/QALY gained
Saxagliptine 33,023 10.55
Pioglitazone 37,019 10.42
Incremental Dominant
Comparator Costs (R$) LYG Cost/QALY gained
Saxagliptine 33,023 12.17
Pioglitazone 37,019 12.16
Incremental Dominant
Saxagliptine + Metformin 
versus 
Rosiglitazone + Metformin
Comparator Costs (R$) QALY Cost/QALY gained
Saxagliptine 33,023 10.55
Rosiglitazone 36,898 10.41
Incremental Dominant
Comparator Costs (R$) LYG Cost/LYG gained
Saxagliptine 33,023 12.17
Rosiglitazone 36,898 12.15
Incremental Dominant
QALY, quality-adjusted life years; LYG, life year gained.
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The discrete event simulation model used in this study, 
named the UKPDS Outcomes Model, has significant ad-
vantages over other DM simulation models: (1) it was 
designed to properly assess interventions that affect risk 
factors with well-established association with DM2-relat-
ed complications; (2) the model can be used to simulate 
health outcomes in populations with different baseline 
characteristics and risk factors26; (3) it used UKPDS data, 
which is one of the most important studies on DM already 
conducted and with results that are considered evidence of 
high level in the specialization, although it has some known 
limitations such as not presenting diabetic neuropathy as 
one of the assessed complications15. In addition, the main 
source of data related to costs was an observational study 
that investigated the specific context of patients treated in 
the private health care system in Brazil (DIAPS79)27.
Some limitations of the model should be mentioned. 
Not all the DM complications are included in the model 
and it was assumed that the negative impact on the quality 
of life is caused only by complications (neither the progres-
sion of disease severity itself nor the therapeutic strategies 
are linked to decreases of utility in the model). Addition-
ally, the utility values were obtained from other countries 
due to lack of local data. New studies are needed to obtain 
utility data and additional economic analyses, and this 
could broaden knowledge about the impacts of new thera-
peutic strategies for the control of blood glucose, support-
ing multi-criteria decision-making analysis in Brazil.
CONCLUSION
From the perspective of private paying source, it is project-
ed that that adding SAX to MF saves costs when compared 
to the addition of ROS or PIO in patients with DM2 that 
have not reached the HbA1c objective with MF mono-
therapy. The BIM of SAX inclusion in the reimbursement 
lists of health plans indicated significant savings within the 
three-year horizon.
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